Estradiol And Norethindrone Acetate Tablet
Product Images NDC 50090-8004

This is a description of Figure 1a showing the mean baseline-uncorrected estradiol and estrone serum concentration-time profiles after multiple doses of Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg. The data includes the concentration levels of a-Estradiol and Estrone over time for a sample size of 24.*

This is a description of a mean baseline-uncorrected norethindrone serum concentration-time profile following multiple doses of Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg, with a sample size of N=24. The table shows the concentration in ng/mL over different time intervals.*

This text provides information on the number of moderate to severe hot flushes recorded in a study using Estradiol Norethindrone Acetate Tablets 0.5 mg 0.1 mg. The mean number of hot flushes is shown for weeks 0 through 12, with placebo data also included for comparison.*

This is a description of a study on patients treated with Estradiol and Norethindrone Acetate Tablets 1 mg/0.5 mg. The data shows the percentage of women with no bleeding or spotting at any cycle through Cycle 13 in the Intent to Treat Population. It also mentions that missing data was handled by carrying forward the bleeding value from the last reported day (LOCF).*

This is a figure showing the percentage of women with no bleeding or spotting at any cycle through Cycle 6 while being treated with estradiol and norethindrone acetate tablets (0.5 mg estradiol/0.1 mg norethindrone). The data is presented for the Intent to Treat Population using LOCF methodology.*

This text provides data on the percentage change in Bone Mineral Density for different treatment groups using Estradiol and Norethindrone Acetate tablets and Estradiol alone. The study employed Intent to Treat Analysis with Last Observation Carried Forward. The changes in Lumbar Spine Bone Mineral Density were evaluated. The text includes information on the number of participants in each treatment group. The results are presented in the form of a figure and indicate the Lunar Month cycle being used in the study.*

This text provides an evaluation of relative and absolute risks seen in the Estrogen Plus Progestin Substudy of the Women's Health Initiative (WHI) over an average of 5.6 years. The table shows the comparison of risks between the group receiving CEMPA CE/MPA and the placebo group, including data on various health events such as CHD events, MI, strokes, breast cancer, fractures, and mortality. The results are based on centrally adjudicated data, and confidence intervals are presented for each risk comparison. The table also includes information on the global index, which combines several significant health events to assess overall risk. The adaptations in this text are sourced from various WHI publications, available for viewing at the specific website mentioned in the text.*

This text provides important information about estradiol and norethindrone acetate tablets, a combination of estrogen and progestogen. It highlights the risks associated with using estrogens or progestogens in preventing heart disease, heart attacks, strokes, dementia, breast cancer, blood clots, and cancer of the uterus. It also emphasizes the importance of discussing with healthcare providers regularly about the necessity of treatment with these tablets, as the impact on the mentioned health conditions may vary depending on the individual.*

This is a set of color-coded instructions for taking pills. The pills should be taken in the order from left to right each week, as indicated by the varying colors and labels provided.*

This table provides detailed data on treatment-emergent adverse reactions of Estradiol and Norethindrone Acetate tablets. The observed adverse reactions are reported with frequencies higher than 5 percent, irrespective of their relationship to the medication. Key areas evaluated include symptoms related to endometrial vasomotor, osteoporosis, body pain, digestive system, nervous system, urogenital system, respiratory system, metabolic, and nutritional aspects among others.*

The text describes pharmacokinetic parameters after the administration of tablets containing Estradiol and Norethindrone Acetate to healthy postmenopausal women. It includes values for Estradiol, Estrone, and Norethindrone, such as AUC, Cmax (maximum plasma concentration), and half-life. The data is presented for different dosages of the tablets, providing valuable information on the drug's distribution and elimination in the body for clinical evaluation.*